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(age, BMI and presence of amiodarone or metabolic inducers) and 
genetic variables (genetic variants in CYP2C9, VKORC1, CYP4F2 
and APOE genes). Our objective was to test the performance of the 
EU-PACT algorithm in our cohort of patients. Assess the influence of 
factors included in our algorithm but not considered in the EU-PACT 
algorithm, specifically CYP4F2 and APOE variants, and concomitant 
use of metabolic inducers.
Patients (or Materials) and Methods: We evaluated the performance 
of the EU-PACT algorithm in our cohort (HULP) using coefficient 
of determination (R2). To investigate the contribution of vatiants in 
CYP4F2 and APOE, and concomitant metabolic inducers, we com-
pared the real acenocoumarol doses of patients with these variables 
and those doses predicted by both models. A third model was built 
using as independent variables the dose predicted using EUPACT 
algorithm in our cohort, APOE and CYP4F2 variants, and concomi-
tant metabolic inducers. Paired McNemar’s test was used to compare 
both R2.
Results: Variability explained by the EU-PACT’s algorithm when 
applied to our (HULP) cohort was 44.4%. The real mean dose in 
patients with at least 1 of the evaluated variables (CYP4F2, APOE 
variants or metabolic inducers) was 19.3 (8.1) mg/week while the 
dose calculated by the HULP-algorithm was almost the same (19.0 
[5.4] mg/week) and the EU-PACT’s model underestimates almost 3 
mg (16.0 [6.2] mg/week), P < 0.001. The third model, evaluating 
the contribution of CYP4F2 and APOE variants and concomitant 
metabolic inducers, is able to increase the R2 from a 44.4% observed 
with the EU-PACT algorithm to 47.5% (P < 0.05).
Conclusion: EU-PACT shows a reasonable performance in an inde-
pendent cohort with VTD. Inclusion of other known genes involved 
in high dose requirements as CYP4F2 and ApoE and enzyme inducer 
drugs, all included in HULP algorithm, seems to improve prediction 
in acenocoumarol dosing.
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Introduction: Eating behavior has been shown to be affected by the 
brain-derived neurotrophic factor (BDNF). In the present work, we 
have aimed to investigate whether BDNF genetic variability may 
influence physiological and psychopathological features in patients 
with eating disorders (ED) and/or modulate the risk for the disorder.
Patients (or Materials) and Methods: One hundred twenty unrelated 
female patients with anorexia or bulimia nervosa (AN, BN) and 125 
healthy controls were genotyped for BDNF single nucleotide poly-
morphisms (SNPs). Associated psychopathological characteristics 
were assessed by the EDI-2 and SCL-90R inventories.
Results: With regard to physiological parameters, the rs16917237 
TT genotype was associated with increased minimum weight (60.6 
[19.3] vs 50.4 [11.9] kg; P < 0.05) and BMI (23.3 [7.9] vs 19.3 
[4.1]; P < 0.05) in the whole population of patients with ED. The 
risk study showed that only the rs11030119 AA genotype increased 
the risk for AN (OR = 5.23 [1.32–20.98], p = 0.02), although the 
association lost significance after Bonferroni correction. AN patients 
who harbored the -270CC genotype scored higher than CT carriers 
in the Interpersonal Distrust scale of the EDI-2 questionnaire (6.9 
[4.4] vs 2.9 [3.6]; Bonferroni P < 0.05). In the same manner, car-
riers of rs10835210 CC wildtype genotype showed higher scores 
for the Drive for Thinness scale (13.5 [5.0] vs 9.6 [6.0] for patients 
with the variant allele; Bonferroni P < 0.05). Finally, the haplotype 
study showed that 2 combinations (haplotypes *4 and *7) showed 
significantly higher scores in several scales of the EDI-2 and SCL-90R 
inventories than those with the most common haplotype *1. 
Table.  Descriptive and clinical variables of patients with anorexia 
nervosa (AN) or bulimia nervosa (BN) and healthy controls. 
Mean (SD) values are shown.
AN BN Controls P
Age, years 25.4 (7.67) 26.88 (6.88) 22.18 (6.13) NS
Height, m 1.61 (0.07) 1.61 (0.05) 1.62 (0.05) NS
Weight, kg 45.56 (6.44) 60.16 (3.84) 58.1 (9.33) < 0.05a
BMI, kg/m2 17.6 (2.31) 22.88 (5.27) 22.13 (3.45) < 0.05a
Age at onset, 17.16 (5.07) 19.57 (6.7)
Mean duration of 
illness, y
19.63 (7.25) 19.62 (5.9)
Total EDI-2 score 87.46 (42.67) 115.64 (41.88)
GSI (SCL-90R) score 1.54 (0.81) 1.97 (0.89)
PST (SCL-90R) score 60.72 (20.7) 71.02 (17.8)
PSDI (SCL-90R) score 2.17 (0.75) 2.41 (0.57)
Conclusion: Variability in the BDNF gene locus may contribute to 
psychopathological features that are commonly found in ED patients.
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Introduction: Acenocoumarol is an oral anticoagulant of the cou-
marin type. These anticoagulants have a narrow therapeutic index 
and are characterized by a large interpatient variability that can be 
explained by numerous factors, including genetic factors. Dose vari-
ability due to polymorphisms in the VKORC1 and the CYP2C9 genes 
has been well characterized. The aim of our study was to investigate 
the potential association between ABCB1 polymorphisms and the 
time-to-achieve stability during acenocoumarol treatment.
Patients (or Materials) and Methods: We conducted a prospective 
observational study on 115 hospitalized patients, aged 18 years and 
over and starting acenocoumarol. Collected data included sex, age, 
anticoagulant indication, INR measurements, acenocoumarol doses, 
comorbidities, comedications, and genotype (ABCB1 c.3435C> T 
and c.2677G> T/A). Patients were followed from the date of the first 
acenocoumarol administration until time-to-achieve stability or the 
end of the observation period of 35 days. Time-to achieve stability 
was defined as the first 3 consecutive INR measurements within the 
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therapeutic range (2.0–3.0 + 0.2), encompassing a period of at least 
2 weeks and with a maximum difference between the mean daily 
dosages of 25%. The association between genotypes and time-to-
achieve stability was evaluated using survival analysis techniques. A 
Cox proportional hazard model was used to assess the relative risk 
of achieving a first period of stability in the follow-up period.
Results: Results showed that time-to-achieve treatment stability 
with acenocoumarol is decreased significantly for carriers of ABCB1 
c.3435TT genotype and extended in wild-type and heterozygous 
subjects (HR, 2.94 [IC 1.22–7.09]). Similarly, carriers of ABCB1 
c.2677GT or TT genotypes reached more rapidly stability than 
wild-type subjects (HR, 2.15 [IC, 1.07–4.98] and HR, 3.00 [IC, 
1.08–8.36], respectively). The other tested polymorphisms (CYP2C9, 
CYP2C19 and VKORC1) had no influence on the time-to-achieve-
stability.
Conclusion: Our results suggest for the first time that time-to-achieve 
stability with acenocoumarol is shorter to reach in carriers of ABCB1 
c.3435TT and carriers of ABCB1 c.2677GT/TT combined. Further 
studies are required to assess whether the identification of ABCB1 
genotypes before treatment with acenocoumarol may be useful for a 
safer and rapid anticoagulation stabilization.
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Introduction: Several pharmacogenetic algorithms have been devel-
oped to achieve the desired acenocoumarol therapeutic range as soon 
as possible to reduce the risk of hemorrhagic events or progression of 
the thrombotic disease. The main SNPs recognized to influence the 
adequate acenocoumarol dosing are located in CYP2C9, VKORC1, 
and recently CYP4F2 and APOE genes (Borobia et al. PLoS One 
7(7):e41360). POR is required for drug metabolism by all microso-
mal cytochrome P450 enzymes and has been arisen their influence in 
warfarin dose. Our objective is to investigate the influence of POR 
genetic variants on acenocoumarol dosing.
Patients (or Materials) and Methods: Patients with thromboem-
bolic disease, atrial fibrillation, and heart valve replacement were 
prospectively recruited. Blood samples were taken for genotyping 
genetic variants of VKORC1 (rs9923231), CYP2C9 (*2 - rs1799853 
and *3 - rs1057910), CYP4F2 (rs2108622), APOE (rs7412), and 
POR (rs1057868 and rs2868177). Demographics (sex, age, body 
weight, and height) as well as acenocoumarol stable dose, INR, and 
concurrent medications were also recorded. The influence of POR 
genetic variants on acenocoumarol stable dose was ascertained using 
a generalized linear model (GLM). In a baseline GML model an 
algorithm for dosing was developed including clinical factors (age, 
body mass index [BMI], pathology, and concomitant drugs) and 
VKORC1, CYP2C9, CYP4F2, and APOE genetic variations. A sec-
ond algorithm was developed adding to the baseline GLM POR SNPs 
as independent factors including significant interactions with other 
genetic variants. Paired McNemar’s test was used to compare the 
R2 of both models to evaluate POR SNPs contribution.
Results: A total of 282 Caucasian patients were included (147 with 
thromboembolic disease, 68 with atrial fibrillation, and 67 with heart 
valve replacement). Genetic information, including PORxCYP2C9 
and PORxCYP4F2 interactions were introduced in the GLM. Also 
demographic and clinical information were added. Only CYP2C9 
*1/*3xPOR G/G (rs2868177) and CYP2C9*1/*2xPOR G/G 
(rs2868177) interactions reached the statistically significance (P = 0.04 
and 0.018, respectively). Adding these interaction to the algorithm 
including age, BMI, pathology, enzyme inducers, amiodarone treat-
ment, CYP2C9 *1/*3, CYP2C9 mut/mut (*2/*2, *2/*3 and *3/*3), 
VKORC1 A/G, VKORC1 A/A, CYP4F2 T/T and APOE T/T geno-
types, R42 increased from 55.6% to 56.3%. This difference in R2 do 
not reached statistical significance (P = 0.50).
Conclusion: POR (rs2868177) modulate the influence of CYP2C9 
genetic variants on acenocoumarol doses, but its global influence 
appears to be low.
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Introduction: The objective of the study was to determine the renal 
clearance of metformin in healthy Caucasian volunteers with and 
without the polymorphism c.808G> T (rs316019) in OCT2 and the 
relevance of gene–gene interactions between c.808 (G> T) and the 
promoter SNP g.-66T> C (rs2252281) in MATE1 and between c.808 
(G> T) and the OCT1 reduced-function diplotypes.
Patients (or Materials) and Methods: Fifty healthy volunteers geno-
typed for the c.808 G> Twere enrolled in the study. Thus, there were 
25 GG, 20 GT, and 5 TT. The pharmacokinetics of a 500-mg single 
oral dose of metformin was studied.
Results: The renal and secretory clearance of metformin was 
increased for the volunteers with minor alleles in c.808 (G> T) who 
also were homozygous for the reference in the promoter variant g.-66 
T> C in MATE1: Clrenal: GG, GT, TT: 28.1 L/h, 34.5 L/h, and 44.8 
L/h, P = 0.004; Clsec:GG, GT, TT: 21.4 L/h, 27.8 L/h and 37.6 L/h, 
P = 0.005. Inindividuals heterozygous for both c.808 (G> T) and 
g.-66 T> C variants metformin renal and secretory clearance was 
reduced compared with reference individuals with the g.-66 T> C 
genotype: Clrenal: 34.5L/h, 28.3 L/h, P = 0.022; CLsec: 27.8 L/h 
21.6 L/h, P = 0.022.
Conclusion: Counteracting effects of the genetic variations OCT2 
c.808 (G> T) and MATE1 g.-66 T> C on the renal elimination of 
metformin has been demonstrated. The results suggested that OCT2 
c.808 (G> T) has a dominant geno- to pheno-type correlation. But 
also that the genetic variation in MATE1 g.-66 T> C can counteract 
the increased clearance of metformin associated with OCT2 c.808 
(G> T).
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Introduction: There is a large interindividual variation in tacrolimus 
(TAC) disposition. Genetic information (mainly CYP3A5) has been 
shown to influence TAC pharmacokinetics and potentially contrib-
